In Alzheimer’s disease, evidence suggests that Δ9-THC therapy may inhibit acetylcholinesterase [166], reduce amyloid-β levels [99] and hippocampal neurogenesis [100], and induce brain-derived neurotrophic factor release through mixed CB1 and CB2 modulation [96,167]. This evidence concerns the gene CNR1 and early-onset autosomal dominant Alzheimer disease.